Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 1Glioblastoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Cancer 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × ralimetinib × Clear all
NCT02860780 2018-12-14

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
9 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡